Call: (+91) 73979 11126
Name : Tricosilk Composition : Minoxidil (2% w/v) + Aminexil (1.5% w/v) Manufactured by : Ajanta Pharma Ltd Packing : 60ml
Tricosilk Solution is used to treat hair loss. It works by increasing blood flow to the hair follicles which further prevents hair loss and stimulates re-growth resulting in longer, thicker and increased ners of hair.
In Hair loss Tricosilk Solution is a medicine used to treat common hereditary hair loss. It prevents further hair loss and helps hair to regrow. It works by increasing blood flow to the hair follicles on your scalp, which prevents hair cell death and also enhances new hair growth. It is most effective for baldness or thinning at the top of the scalp but less effective at the front or for receding hairline. Benefits are less likely if you have been bald for many years or have a large area of hair loss. Tricosilk Solution is not suitable for sudden or unexplained hair loss. It is considered as a safe medicine. However, hair that has regrown may disappear after a few months. Regrowth of hair can be beneficial to your mood, self-esteem as well as your appearance, but you need to use it regularly to get the benefits.
Tricosilk Solution is a combination of two hair growth promoters: Minoxidil and Aminexil. Minoxidil is a vasodilator, meaning it widens the blood vessels and provides better blood flow to the hair follicles. This prevents hair loss and stimulates re-growth resulting in longer, thicker and increased numbers of hair. Aminexil suppresses an enzyme which causes buildup of a protein (collagen) around the hair follicles leading to hair loss.
Product Enquiry
Select you countryAfghanistanAlbaniaAlgeriaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanThe BahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCentral African RepublicChadChileChinaColombiaComorosCongoCosta RicaCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFijiFinlandFranceGabonThe GambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyamaicaJapanJordanKazakhstanKenyaKiribatiKorea, NorthKorea, SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorth MacedoniaNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri LankaSudanSudan, SouthSurinameSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamYemenZambiaZimbabwe
Log in